Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINSTREAM: Sacubitril/Valsartan for Prevention of Cardiotoxicity in Breast Cancer
NCT05465031Phase 4Recruiting
- Sponsor
- Silesian Center for Heart Diseases
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Cardiotoxicity and heart failure (HF) comparing Sacubitril/Valsartan with Placebo (2 arms). Primary endpoint: Occurrence of a reduction in LVEF by ≥ 5% at 24 months. Started Apr 2024; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
Cardiotoxicityheart failure (HF)
Beyond the preview
Go deeper on NCT05465031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465031.